CD19-specific chimeric antigen receptor T-cell therapy (CD19 CAR T) has shown high rates of initial response among children and young adults with refractory/relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL)1–6. The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.